Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05701345
Other study ID # OMNI_MDD_01
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date March 9, 2023
Est. completion date December 15, 2024

Study information

Verified date March 2023
Source Omni C&S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks. The investigator would like to confirm evaluate the safety and efficacy of the wearable visual device(HMD)-VR-based software medical device effect of improving depressive disorder in patients.


Description:

Trial subject is a mild and moderate patients diagnosed with depressive disorder The test group is a wearable visual device(HMD)-VR-based software medical device(OMNIFIT DTx-MDD) and patients who have received standard treatment. The number of subjects is 162(Two groups, 81 people per group, 15% dropout rate included) Participating institutions are five including Catholic University of Korea Seoul ST. The clinical trial method is as follows. Subjects who are satisfied with all selection/exclusion criteria and agree to participate in clinical trials are classified into groups that combine test software medical devices and standard treatment based on Visit 2 (Baseline) and groups that perform simple standard treatment. After that, necessary tests are performed at 2, 4, 6, and 8 weeks, and changes in depressive disorder and depressive disorder evaluation scale are confirmed, and safety is evaluated.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 162
Est. completion date December 15, 2024
Est. primary completion date December 15, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 64 Years
Eligibility Inclusion Criteria: 1. right-handed men and women 2. If you agree to participate in this clinical trial and voluntarily sign a written consent form 3. If you can understand and cooperate with the contents of this clinical trial 4. If you have a wireless internet(Wifi) environment 5. Diagnosed by a psychiatrist as major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorder 5th edition(DSM-5) or other specified depressive disorder 6. Mild or moderate depressive episodes with a total hdrs score of 7 or more and 24 or less 7. If there was no change in the type and dose of antidepressants and antipsychotics taken within 4 weeks prior to participation in this clinical trial Exclusion Criteria: 1. if you are pregnant 2. Schizophrenia, schizoaffective disorder, schizophrenic disorder, or a psychotic disorder not otherwise classified or diagnosed in the past 3. If you have current bipolar disorder or have been diagnosed with bipolar disorder in your past history 4. Accompanied by organic mental disorder, epilepsy/convulsive disorder 5. Current eating disorders, alcohol and other substance-related disorders, and obsessive-compulsive disorder 6. Uncontrolled and unstable clinically significant physical condition 7. In cases where psychiatric evaluation and maintenance of treatment are difficult due to other serious acute physical illnesses 8. If you have received electroconvulsive therapy and transcranial magnetic stimulation therapy for a current depressive episode 9. Treatment-resistant depressive disorder for which there was no effect even after using two or more antidepressants in sufficient doses and for a sufficient period of time (6 weeks) for the current depressive episode 10. Currently requiring inpatient treatment for a psychiatric disorder other than depressive disorder (ex. alcohol dependence, substance abuse) 11. If the risk of suicide, self-harm, or other harm is judged to be high according to the evaluation of the study director 12. Current depressive episode accompanied by psychotic symptoms 13. Cases in which a therapeutic intervention for a clinical trial cannot be performed due to deterioration of eyesight or hearing 14. Current treatment with mood stabilizers (lithium, valproate, carbamazepine, lamotrigine) for depressive episodes 15. Those who are unable to participate in clinical trials due to the judgment of other researchers 16. Those who cannot read the consent form (ex. illiterate, foreigners)

Study Design


Intervention

Device:
OMNIFIT DTx-MDD
This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
Other:
standard treatment
It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders. Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.

Locations

Country Name City State
Korea, Republic of Inje University Ilsan Palk Hospital Ilsan
Korea, Republic of Jeju National University Hospital Jeju
Korea, Republic of Seoul ST. Mary's Hospital Seoul
Korea, Republic of Yeouido ST. Mary's Hospital Seoul
Korea, Republic of ST. Vincent's Hospital Suwon

Sponsors (1)

Lead Sponsor Collaborator
Omni C&S

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of change in Hamilton Depression Rating Scale total score The comparison of changes in Hamilton Depression Rating Scale total score between each group is evaluated by Student t-test performing two independent samples.
The minimum value is 0 points and the maximum value is 52 points, with higher scores indicating more severe depressive symptoms.
8 weeks
Secondary Comparison of response rate and remission rate by Hamilton Depression Rating Scale chi-squared test or Fisher's exact test is performed to compare response rates (reduction of 50% or more from baseline) and remission rates (Hamilton Depression Rating Scale total score of 6 points or less) by Hamilton Depression Rating Scale between and within groups, and the within-group comparison is based on the frequency of improvement. Evaluate by performing McNemar test for The minimum value is 0 points and the maximum value is 52 points, with higher scores indicating more severe depressive symptoms. 8 weeks
Secondary Comparison of Changes in Patient Health Questionnaire-9 Scores The comparison of changes in the Patient Health Questionnaire-9 score between each group is performed by an independent two-sample student t-test, and the comparison within groups is evaluated by a paired-sample t-test.
The Patient Health Questionnaire-9 score has a minimum value of 0 and a maximum value of 27 points, with higher scores indicating more severe depression.
8 weeks
Secondary Comparison of Changes in Clinical Global Impression - Severity & Clinical Global Impression The comparison of changes in the Clinical Global Impression - Severity & Clinical Global Impression - Improvement scores between each group is performed by an independent two-sample student t-test, and the comparison within groups is evaluated by a paired-sample t-test.
The Clinical Global Impression - Severity & Clinical Global Impression has a minimum value of 0 and a maximum value of 7 points, with higher scores indicating more severe depression.
8 weeks
Secondary Comparison of side effects Comparison of side effects between each group is evaluated by performing a chi-squared test or Fisher's exact test after using the test software medical device. 8 weeks
Secondary Comparison of adverse events Comparison of side adverse events each group is evaluated by performing a chi-squared test or Fisher's exact test after using the test software medical device. 8 weeks
Secondary Comparison of dropout rates Comparison of dropout rates events each group is evaluated by performing a chi-squared test or Fisher's exact test after using the test software medical device. 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4